Keyphrases
ATTR Amyloidosis
100%
Cardiac Involvement
56%
Bone Scintigraphy
50%
Technetium-99m
50%
Transthyretin Amyloidosis
50%
ATTRv
50%
Early Follow-up
50%
High-sensitivity Cardiac Troponin
50%
Light Chain Amyloidosis
50%
Liver Stiffness
50%
Immunoglobulin Light Chains
50%
Diagnostic Performance
50%
Liver Involvement
50%
Wild-type Transthyretin Amyloidosis
50%
Transthyretin Gene
42%
Transthyretin Stabilizers
37%
AL Amyloidosis
31%
Gene Variants
30%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
30%
Cardiomyopathy
26%
NYHA Class
25%
Tracer Uptake
25%
Body Ratio
25%
Patisiran
25%
Whole-body
25%
Hereditary Transthyretin
22%
Cardiac Biomarkers
22%
Consensus Criteria
18%
Scintigraphy
18%
Serum Amyloid A
18%
Early Markers
12%
Echocardiography
12%
Silencer
12%
Thickness Parameter
12%
Treatment Response
12%
Wall Thickness
12%
Disease Progression
12%
Diastolic Parameters
12%
Specific Response
12%
Troponin
12%
Retrospective Cohort Study
12%
Quantitative Biomarkers
12%
Potential Treatments
12%
Validation Data
10%
Predictive Ability
10%
Hs-cTnT
10%
Binary Logistic Regression Model
10%
Negative Predictive Value
10%
Retrospective Case-Control Design
10%
High Risk
10%
Medicine and Dentistry
Transthyretin
58%
Bone Scintigraphy
50%
Technetium-99
50%
ATTR Amyloidosis
50%
Immunoglobulin Light Chain
50%
AL Amyloidosis
50%
Diagnostic Performance
50%
Amyloidosis
46%
Rib
41%
Scintigraphy
25%
Serum Amyloid P
25%
Patisiran
20%
Radioactive Tracer
20%
New York Heart Association Class
20%
Silencer Gene
10%
Troponin T
10%
Echocardiography
10%
Disease Exacerbation
10%
Treatment Response
10%
Retrospective Cohort Study
10%
Biological Marker
10%
Sensitivity and Specificity
8%
Cardiomyopathy
8%
Liver Biopsy
8%
Transient Elastography
8%
